Scotiabank lowered the firm’s price target on Alnylam (ALNY) to $300 from $310 and keeps an Outperform rating on the shares. The firm is encouraged by the company’s Q4 results, which were marked by consistent revenue growth, the analyst tells investors. The firm expects the company to continue to execute on clinical, regulatory, and commercial fronts, which should drive the company to sustainable profitability by year end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Strong Buy Recommendation for Alnylam Pharma Amid Upcoming PDUFA Date and Promising Growth Prospects
- Alnylam Pharmaceuticals Reports Strong 2024 Growth
- Alnylam Pharma Receives Buy Rating: Strong Revenue Growth, Regulatory Approvals, and International Expansion Fuel Positive Outlook
- Alnylam Pharma’s Promising Outlook: Buy Rating Backed by Strong Sales, Strategic Developments, and Profitability Potential
- Alnylam sees FY25 revenue $2.05B-$2.25B, consensus $2.68B
Questions or Comments about the article? Write to editor@tipranks.com